Mario Thomas

Senior Vice President at Ontario Centres of Excellence

Mario Thomas

Mario Thomas

Senior Vice President at Ontario Centres of Excellence

Overview
Career Highlights

Entomed SA
Terragen Discovery, Inc.

RelSci Relationships

261

Number of Boards

6

Birthday

1951

Age

67

Relationships
RelSci Relationships are individuals Mario Thomas likely has professional access to. A relationship does not necessarily indicate a personal connection.

Managing Director at Sanderling Ventures

Relationship likelihood: Strong

Director-Regional Commercialization at Ontario Centres of Excellence

Relationship likelihood: Strong

Director-Regional Commercialization at Ontario Centres of Excellence

Relationship likelihood: Strong

Director-Technology Transfer Networks at Ontario Centres of Excellence

Relationship likelihood: Strong

Director-Programs at Ontario Centres of Excellence

Relationship likelihood: Strong

Director-Planning at Ontario Centres of Excellence

Relationship likelihood: Strong

President at Medicago USA, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Ogeda SA

Relationship likelihood: Strong

Co-Founder at Nanotechnology Network of Ontario

Relationship likelihood: Strong

Portfolio Manager at Fonds de Solidarité FTQ

Relationship likelihood: Strong

Paths to Mario Thomas
Potential Connections via
Relationship Science
You
Mario Thomas
Senior Vice President at Ontario Centres of Excellence
Education
Ph.D. in Chemistry

The oldest centre of education in Canada, and was the first institution in North America to offer higher education in French.

Diploma in Business Administration

HEC Montréal is a university business school whose reputation as a leader in teaching and research is recognized in Québec, Canada, and around the world. HEC Montréal is a French-language university institution offering internationally renowned management education and research. The School has been training future managers who contribute to our society’s growth and prosperity, since 1907. HEC Montréal’s excellence in management teaching and research is recognized worldwide. As proof, the School was the first in North America to be awarded the three most prestigious international accreditations in its field: AACSB International, EQUIS and AMBA. HEC Montréal is a French-language institution solidly rooted in its community and open to the world. It is an international-calibre university business school that contributes to our society’s prosperity by providing leadership in all its spheres of activity, i.e. teaching at all levels, research and serving the community.

Career History
Senior Vice President
2009 - Current

Founded in 1987, the Ontario Centres of Excellence is a venture capital firm located in Toronto, Ontario. They are a subsidiary of the Ontario Centres of Excellence, Inc., a not-for-profit, member-based corporation that focuses on furthering the research and commercialization of marketable products and services that can drive economic growth in Ontario. The Ontario Centres for Excellence consists of: Communications and Information Technology Ontario (CITO), the Centre for Research in Earth and Space Technology (CRESTech), Materials and Manufacturing Ontario (MMO) and Photonics Research Ontario (PRO) and the Centre of Excellence for Energy

Vice President
2002 - 2009

T²C² seeks to identify (in universities, research centers and industry) business opportunities and turn them into real businesses. They invest in health sciences, with an emphasis on biotechnology, pharmaceuticals and medical equipment.Criteria that are necessary for the selection of a project are: excellent quality of science and technology, complementarities and equilibrium of the team, intellectual property and market potential.

Vice President & Partner
2002 - 2009
Boards & Committees
Member, Board of Directors
Current

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1.TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug.TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Member, Board of Directors
2003 - 2007

Biogentis, Inc. is a biopharmaceutical company, which designs anddevelops healthcare solutions in the field of advanced wound care and regenerative medicines. The company provides three technology platforms: Dermalink, a fibronectin-based product for chronic wound healing, CyanoStrip, a wound closure system and a self-assembly tissue engineering technology. It is located in Montréal, Canada

Director
2003 - 2012

9342-8530 Québec, Inc. develops and provides immunoassay and molecular diagnostic tests for early cancers. It offers prostate, colorectal, previstage GCC, lung and diagnostic test and other research and development services. The company was founded by Yves Fradet on December 13, 1994 and is headquartered in Quebec, Canada.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mario Thomas. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mario Thomas's profile does not indicate a business or promotional relationship of any kind between RelSci and Mario Thomas.